The Clinical Observation And Economic Analysis In The Therapeutic Schemes Of Ozagrel Affiliated With Sodium Ferulate For Cerebral Infarction

Cerebral infarction has became a common and frequently encountered disease which seriously threaten the physical health of people.In recent years, the upward trend incidence of cerebral infarction and the younger trend seriously endangering people's health and quality of life, and the same time, makes heavy burden to the state of medical,economic and social.The treatment of cerebral infarction include ultra-early,acute and convalescent phase, ultra-early thrombolytic therapy is considered the best treatment methods, but such treatment has strict time limit, only within six hours after the onset. And, because such treatment has certain degree risk, willing to accept is even less. Therefore, the search for more effective treatment methods of the acute stage have important clinical significance. Taking into account there are numerous factors involved in the development process of cerebral infarction, and now the treatment of acute ischemic stroke drug only against a single link or single factor.People trying tochoose a variety of drugs combined in order to achieve a more rational and effective treatment.Ozagrel is a TX sis, specific to the inhibition of thromboxane A2 (TXA2) syntheses , thus inhibit TXA2 synthesis , reduce the concentration of TXA2:also can promote the formation of PGI2 and improve the balance between PGI2 and TXA2. Sodium ferulate is one of cinnamic acid derivative, is an alkaloid, because of their special phenolic groups can scavenge free radicals, benzene structure anti ET. Therefore, the drug has the dual role of protecting endothelial cells and antagonist vascular endothelin. In theory, in the treatment of acute ischemic stroke, combined TX sis and endothelin receptor antagonists can regulate the systolic and diastolic functional in acute cerebral ischemic stroke, and more links to intervene to ease the development of cerebral infarction, to achieve good results. The topic will be 93 cases of acute ischemic stroke patients were randomly divided into three groups: group A combination ozagrel and sodium ferulate, Ozagrel Group B, Group C Application of sodium ferulate treatment. On medication and 14 days after thestroke drug application, measuring scores of China clinical neurological scale and the United States National Institutes of Health Stroke Scale. Three months and six months after treatment to measure the activities of daily living scale. According to the Fourth National Academic Conference on cerebrovascular disease, clinical evaluation standards of effect: basic recovery, significant progress, progress, invalid or deterioration.The total significant efficiency of group A (cured+notable progress) is 73.3 percent, the total efficiency (cured + notable progress + progress) is 93.3 percent; the total significant efficiency of group B is 41.9 percent, the total efficiency is 71.0 percent; the total significant efficiency of group B is 37.5 percent, the total efficiency is 68.8 percent. Compared Group A with Group B and group C, there exists significance in total significant efficiency (P <0.01) and total efficiency (P <0.05), It illustrates than group A can significantly improve the efficiency and efficient. Result proved that the acute phase of cerebral infarction, combined with Ozagrel sodium ferulate, against different mechanisms of cerebral infarction.To some extent, synergy can be achieved, so better results of the treatment to cerebral infarction can be achieved.More effective in the treatment of cerebral infarction, we need to focus on the economic costs due to the heavy financial burden of the families and the state to achieve cost-effective and reasonable treatment.In view of this, the cost of drugs and therapeutic efficacy started to be discussed applying the principles of economics. Comprehensive evaluation of the cost-effectiveness of drug therapy to be better ways to solve problems. Than a single drug combination increased financial burden. Well, this increase in terms of cost-effectiveness analysis is a basis for our therapy.Therefore, the issue makes the economics evaluation of drug of the medicines.In this study, we can see that three types of treatment programs need 59.14 yuan, 48.99 yuan and 47.62 yuan for each unit effect. While the minimum cost of the treatment group C, but its therapeutic effects are minimum, it is not necessarily the most rational treatmentprograms. Later on its incremental cost-effectiveness analysis found that in group A, group B and group C, every 1% increase in efficiency cost 91.49 yuan, 92.00 yuan. This shows that in three types, the program of group A have the highest efficiency compared with Group B, it cost only 91.49 yuan, which was significantly lower than group B. Therefore, the group is more reasonable.